ORLANDO, Fla., May 17 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc.
(Nasdaq: INGN) today provided an update of its ongoing clinical development
of INGN 401, a nanoparticle formulation of the tumor suppressor gene FUS1.
New preclinical data highlighting the potential of INGN 401 alone and in combination
with Iressa(R) (Gefitinib) in the treatment of non-small cell lung cancer were
reported. The data were presented today (Abstract #7081) at the 41st Annual
Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. Introgen
researchers and their colleagues at The M. D. Anderson Cancer Center (MDACC)
and The University of Texas Southwestern Medical Center are conducting the
studies of INGN 401.
"The preclinical data presented today are very encouraging
because they suggest that INGN 401 may have utility
as a monotherapy and may also help to improve chemotherapy
response rates in patients with lung cancer," said
Sunil Chada, Ph.D., associate vice president, Clinical
Research at Introgen. "The five-year survival of
patients with non-small cell lung cancer is only
15 percent, and these patients have significant unmet
medical needs. These preclinical findings support
the utility of INGN 401 in the treatment of lung
cancer, and support our ongoing Phase 1 clinical
trial of INGN 401 in this disease. The data illustrate
that our nanoparticle delivery system may provide
a novel approach to the systemic delivery of gene-based
Significant inhibition of tumor growth in animal
models of lung cancer was observed following INGN
401 monotherapy treatment compared with untreated
animals. In addition, INGN 401 demonstrated synergistic
activity with Gefitinib, a novel class of anti-cancer
agents that decrease tumor growth by inhibiting growth
factor receptors that promote tumor proliferation.
While Gefitinib can produce dramatic responses in
a small subset of lung cancer patients, most lung
cancers are refractory to its effects. In the reported
studies, nanoparticle delivery of INGN 401 synergized
with Gefitinib in killing lung tumor cells resistant
to Gefitinib alone. Furthermore, in Gefitinib-sensitive
tumors, INGN 401 delivery significantly enhanced
anti- cancer activity.
A Phase 1 clinical trial of INGN 401 in patients
with stage IV non-small cell lung cancer is in progress.
This study is evaluating intravenous delivery of
INGN 401 as monotherapy for patients with advanced
lung cancer who have experienced disease progression
while on chemotherapy.
Introgen holds a licensing agreement with M. D.
Anderson to commercialize products based on licensed
technologies, and has the option to license future
technologies under sponsored research agreements.
The University of Texas Board of Regents own stock
in Introgen. These arrangements are managed in accordance
with M. D. Anderson's conflict of interest policies.
Introgen is a leading developer of biopharmaceutical
products designed to induce therapeutic protein expression
using non-integrating gene agents for the treatment
of cancer and other diseases. Introgen maintains
integrated research, development, manufacturing,
clinical and regulatory departments and operates
a commercial-scale, CGMP manufacturing facility.
Introgen's Website at: http://www.introgen.com
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
SOURCE Introgen Therapeutics, Inc.